Phase 3 N=48 Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
Severe Hemophilia A
Primary: Immunogenicity of Human-cl rhFVIII: Incidence of Inhibitors — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=84 Liraglutide In Overweight Patients With Type 1 Diabetes
Type 1 Diabetes
Primary: HbA1c — 7.77; 7.94; 7.64; 7.60 percent
Phase 3 N=2,670 Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Influenza
Primary: Geometric Mean Titers (GMTs) of Influenza Antibodies Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza…
Phase 3 N=24 Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement
Arthropathy of Knee Joint
Primary: Vancomycin Concentration in Fat — 6.0; 40.5 ug/g — p=0.001
Phase 3 N=788 Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -1.7; -1.0; -1.5; -1.0 Percentage (%) of HbA1c — p=<.0001
Phase 3 N=509 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Overall Survival (OS) — 20.37; 19.75 Months — p=0.6945
Phase 3 N=47 Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Multiple Myeloma
Primary: Number of Patients Able to Collect >=6 x 106 CD34+ Cells/kg in <= 2 Collections. — 11; 0; 14 Participants — p=0.90
Phase 3 N=10 The Bihormonal iLet Bionic Pancreas Feasibility Study
Type 1 Diabetes Mellitus
Primary: Percentage of Time That Valid CGM Glucose Readings Are Captured by the iLet Bionic Pancreas — 89.2; 91.0 percentage of time
Phase 3 N=189 Progesterone for Perimenopausal Night Sweats
Hot Flushes · Night Sweats
Primary: Vasomotor Symptoms (VMS)/ VMS Score - at 12 Weeks — 5.5; 7.1 Units of Vasomotor Symptom Score
Phase 3 N=1,151 Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
Acute Ischemic Stroke · Diabetes · Hyperglycemia
Primary: Number of Participants With a Favorable Modified Rankin Scale (Yes/No) — 119; 123 Participants — p=0.55
Phase 3 N=2,106 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.
Anemia
Primary: Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 — 0.77; 0.68 g/dL — p=<0.001
Phase 3 N=2,761 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
Anemia
Primary: Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 — 1.75; 0.40 g/dL — p=<0.001
Phase 3 N=244 Assessment of Mechanisms of Improved Wound Healing
Burns
Primary: Decrease Hypermetabolism as Measured by Stable Isotope Infusion Study
Phase 3 N=239 Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: Evaluation of the Long-term Safety and Tolerability of Oral Istradefylline (20mg or 40mg/Day [mg/d]) — 141; 98 Participants
Phase 3 N=467 A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
Actinic Keratosis
Primary: Complete Clearance Rate - Percentage of Participants With Treatment Success: Per-Protocol (PP) Population — 12.4; 13.6; 4.8 percentage of participants — p=0.0702